WILLIAM LARY: Open Payments
NPI 1134883432 · HYANNIS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$709 in 35 payments from 15 companies in 2025. Trend: 2023 $202 · 2024 $297 · 2025 $709
Food & beverage: $709
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $188 |
| GlaxoSmithKline, LLC. | 4 | $87 |
| Phathom Pharmaceuticals, Inc. | 4 | $84 |
| ABBVIE INC. | 3 | $69 |
| Novo Nordisk Inc | 3 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $42 |
| Novartis Pharmaceuticals Corporation | 2 | $37 |
| Verona Pharma, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
Products named: FARXIGA, VOQUEZNA, AIRSUPRA, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, ONPATTRO, LEQVIO.
Industry payments across MA — which companies pay providers there.
